Fluphenazine

證據等級: L5

預測適應症: 10 個

Fluphenazine: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Fluphenazine is a first-generation (typical) phenothiazine antipsychotic historically used for the treatment of schizophrenia and related psychotic disorders. The TxGNN model (rank #1) predicts a potential association with Retinal Dystrophy with or without Extraocular Anomalies, with 0 clinical trials and 15 retrieved publications — however, expert mechanistic analysis indicates this association almost certainly reflects drug-induced toxicity rather than a therapeutic opportunity, representing a likely knowledge graph false positive. The most clinically plausible candidate among all 10 predictions is manic bipolar affective disorder (rank #10, evidence level L4), which carries an independent literature basis.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines; known internationally as antipsychotic for schizophrenia/psychosis
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.99%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Fluphenazine is a high-potency dopamine D2 receptor antagonist belonging to the phenothiazine class. Its antipsychotic efficacy — mediated through blockade of mesolimbic D2 receptors — has been demonstrated over decades of clinical use in schizophrenia and related conditions.

However, this prediction raises a critical red flag rather than a repurposing opportunity. Phenothiazine-class antipsychotics, most notably thioridazine, are well-established causes of drug-induced pigmentary retinopathy. Fluphenazine itself carries documented risk of retinal adverse effects. The co-occurrence of “retinal dystrophy” and Fluphenazine in the published literature almost certainly reflects pharmacovigilance reporting of drug-induced harm, not a therapeutic relationship. The TxGNN knowledge graph appears to have captured a drug → disease (toxicity) association and surfaced it as a potential repurposing signal.

In summary, rather than representing a new therapeutic direction, this prediction functions as a safety alert: Fluphenazine exposure carries a risk of contributing to retinal dysfunction, and this direction should not be pursued as a new indication. Any ongoing use of Fluphenazine in any indication should include ophthalmological monitoring protocols.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The 15 retrieved publications cover general ophthalmological topics — orbital infections, congenital eye anomalies, extraocular muscle fibrosis, inherited metabolic eye involvement, and vascular malformations. None specifically investigates Fluphenazine as a treatment for retinal dystrophy. Their presence in the results reflects co-occurrence of phenothiazine-related ophthalmological adverse effects in the biomedical literature, not therapeutic evidence.

PMID	Year	Type	Journal	Key Findings
33806565	2021	—	Int J Mol Sci	Optic nerve and retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM) linked to KIF21A/TUBB3 mutations
38321238	2024	Review	Pediatr Radiol	Differential diagnosis and imaging of pediatric ocular pathologies including congenital and developmental lesions
33447730	2020	Review	Ther Adv Ophthalmol	Eye involvement (retina, cornea, lens, extraocular muscles) across inherited metabolic disorders
38249493	2023	Review	Taiwan J Ophthalmol	Congenital anomalies of lens shape and associated anterior segment dysgenesis
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler syndrome: vitreoretinal degeneration with myopia, cataract, and retinal detachment risk
9416661	1997	Review	Semin Ultrasound CT MR	Orbital infections from sinusitis: five-stage classification and systemic predisposing conditions
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis: levator muscle fibrosis, lid lag, and associated binocular vision disturbances
24413161	2014	Case Report	J Neuroophthalmol	Isolated trochlear-oculomotor synkinesis in a child with congenital cranial dysinnervation disorder
109006	1979	Case Report	Am J Ophthalmol	Two cases of unilateral cryptophthalmia with absent intraocular structures and associated systemic anomalies
19826317	2009	Case Report	Optom Vis Sci	Congenital fibrosis of extraocular muscles exhibiting variable synergistic divergence or adduction

Philippines Market Information

Fluphenazine currently has no registered products in the Philippines (0 authorizations on record). No license table is available.

Safety Considerations

Please refer to the package insert for safety information.

Relevant safety note: Phenothiazine-class drugs, including Fluphenazine, carry documented risk of drug-induced retinal toxicity (pigmentary retinopathy). This adverse effect profile is directly relevant to the top TxGNN prediction and is a primary reason for the Hold recommendation. Ophthalmological baseline assessment and periodic monitoring are warranted for any patient on long-term Fluphenazine therapy.

Other Notable Predictions

Among the 10 TxGNN-predicted indications evaluated, manic bipolar affective disorder (rank #10, TxGNN score 99.98%, evidence level L4) is the only candidate with substantive clinical literature (20 retrieved publications). Key highlights:

A systematic review and expert consensus (PMID 26243837, Clin Psychopharmacol Neurosci, 2015) supports long-acting injectable antipsychotics including fluphenazine decanoate for bipolar disorder maintenance
A retrospective cohort study (PMID 39756485, J Affect Disord, 2025) examines long-acting injectable antipsychotics during manic episodes and their impact on rehospitalization
Case reports (PMID 36779113, Cureus, 2023) document successful off-label use in bipolar disorder comorbid with substance abuse
A systematic review of antipsychotics in anxiety/bipolar disorder (PMID 17017818, J Clin Psychiatry, 2006) provides broader class-level evidence
Mechanistic rationale: dopamine D2 antagonism in mesolimbic pathways is pharmacologically consistent with anti-manic effects; the dopamine hyperactivity hypothesis of mania directly supports D2 blockade

Limitation: Current international guidelines (CANMAT, BAP) do not list typical antipsychotics as first-line for bipolar mania due to significantly higher risk of extrapyramidal symptoms (EPS) and tardive dyskinesia compared to second-generation antipsychotics. No Fluphenazine-specific bipolar RCT has been identified. Recommended classification: Research Question (L4 / S1).

Conclusion and Next Steps

Decision: Hold (Primary prediction: Retinal Dystrophy with or without Extraocular Anomalies)

Rationale: The rank #1 TxGNN prediction almost certainly represents a pharmacovigilance/adverse-effect association rather than a genuine therapeutic opportunity — phenothiazines are documented to cause, not treat, retinal disease, making this a knowledge graph false positive driven by drug-toxicity co-occurrence. No clinical trials exist and no literature provides therapeutic support for this direction.

To proceed with any further evaluation, the following is needed:

Retrieve full pharmacology profile and MOA from DrugBank API (DB00623) to formally document receptor binding and toxicity mechanisms
Obtain the international package insert (FDA.gov or EMA) to document formal contraindications and black box / serious warnings
For bipolar mania (rank #10): conduct a structured systematic literature search specifically for Fluphenazine-focused efficacy data in bipolar disorder to determine whether evidence can be elevated from L4 to L3
Request a knowledge graph audit to distinguish treatment-type associations from adverse-effect-type associations for phenothiazine-class drugs across TxGNN retinal and ocular disease nodes — findings may improve prediction quality across multiple drugs in this class
If Fluphenazine use is pursued in any indication, establish ophthalmological monitoring protocols (baseline fundus exam, annual review) given the documented retinal toxicity risk

⚠️ Disclaimer: This report is for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any application. All predictions should be reviewed by qualified clinical and regulatory professionals.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.